Altimmune to Announce Third Quarter 2020 Financial Results on November 10

November 3, 2020 at 8:00 AM EST

GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2020 financial results on Tuesday, November 10, 2020.

Altimmune management will host a conference call for investors beginning at 8:30 a.m. ET on Tuesday, November 10, 2020 to discuss the financial results and provide a business update.

Conference Call Details

Date: Tuesday, November 10th
Time: 8:30 am Eastern Time
Domestic: 877-300-8521
International: 412-317-6026
Conference ID: 10149733

About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit

Investor Contacts:    
Will Brown   Ashley R. Robinson
Chief Financial Officer   LifeSci Advisors, LLC
Phone: 240-654-1450   617-430-7577
Media Contacts:    
Warren Rizzi    
Sard Verbinnen & Co.    
Phone: 212-687-8080    

Altimmune Logo.png

Source: Altimmune, Inc.


Investor Contact

Will Brown
Chief Financial Officer



Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail